Congressional Cannabis Rescheduling Hearings Signal Policy Momentum
House committee testimony reveals growing bipartisan support for federal cannabis reform as industry awaits regulatory clarity that could unlock institutional investment.
Congressional hearings on cannabis rescheduling are gaining traction as lawmakers from both parties express support for federal policy reform. House committee testimony indicates a shift toward treating cannabis regulation as a public health and economic issue rather than a criminal justice matter. The hearings focus on moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, which would acknowledge medical benefits while maintaining federal oversight.
The rescheduling debate carries massive implications for cannabis operators currently trading at depressed valuations due to regulatory uncertainty. Multi-state operators face effective tax rates exceeding 70% under Section 280E, which prohibits standard business deductions for federally illegal substances. Schedule III classification would eliminate these tax penalties, potentially boosting sector-wide EBITDA margins by 20-30 percentage points.
Institutional investors remain largely sidelined from U.S. cannabis markets due to federal prohibition concerns. Banks, pension funds, and major asset managers avoid the sector despite state-legal operations generating billions in annual revenue. Rescheduling would remove many compliance barriers that prevent mainstream financial participation, potentially triggering significant capital inflows and multiple expansion across cannabis equities.
The testimony comes as state-legal cannabis sales approach $30 billion annually, creating pressure on federal lawmakers to address the disconnect between state and federal law. Industry advocates argue that current scheduling ignores scientific evidence of medical cannabis benefits while hampering research into therapeutic applications. Congressional momentum appears strongest for incremental reform rather than full legalization, making rescheduling the most viable near-term pathway.
Market participants are closely monitoring committee schedules and witness testimony for signals about timeline and scope of potential reforms. Previous rescheduling discussions have stalled due to political gridlock, but current hearings suggest renewed urgency as more states legalize adult-use cannabis. The outcome will determine whether U.S. cannabis companies can access traditional banking services, institutional capital, and federal research funding that could accelerate industry maturation.